| Health industry practices that create conflicts of interest: a policy proposal for academic medical centers TA Brennan, DJ Rothman, L Blank, D Blumenthal, SC Chimonas, ... Jama 295 (4), 429-433, 2006 | 922 | 2006 |
| Professional medical associations and their relationships with industry: a proposal for controlling conflict of interest DJ Rothman, WJ McDonald, CD Berkowitz, SC Chimonas, CD DeAngelis, ... Jama 301 (13), 1367-1372, 2009 | 388 | 2009 |
| Physicians and drug representatives: exploring the dynamics of the relationship S Chimonas, TA Brennan, DJ Rothman Journal of general internal medicine 22, 184-190, 2007 | 205 | 2007 |
| Are financial payments from the pharmaceutical industry associated with physician prescribing? A systematic review AP Mitchell, NU Trivedi, RL Gennarelli, S Chimonas, SM Tabatabai, ... Annals of internal medicine 174 (3), 353-361, 2021 | 191 | 2021 |
| Development of a conceptual map of negative consequences for patients of overuse of medical tests and treatments D Korenstein, S Chimonas, B Barrow, S Keyhani, A Troy, ... JAMA internal medicine 178 (10), 1401-1407, 2018 | 142 | 2018 |
| From disclosure to transparency: the use of company payment data S Chimonas, Z Frosch, DJ Rothman Archives of Internal Medicine 171 (1), 81-86, 2011 | 99 | 2011 |
| (2006) R Brennan, K Oktay Educational Measurement, American Council on Education Pub, 0 | 68 | |
| New federal guidelines for physician–pharmaceutical industry relations: the politics of policy formation S Chimonas, DJ Rothman Health Affairs 24 (4), 949-960, 2005 | 66 | 2005 |
| No more free drug samples? S Chimonas, JP Kassirer PLoS medicine 6 (5), e1000074, 2009 | 63 | 2009 |
| New developments in managing physician-industry relationships DJ Rothman, S Chimonas JAMA 300 (9), 1067-1069, 2008 | 62 | 2008 |
| Trends in industry payments to physicians in the United States from 2014 to 2018 DC Marshall, ES Tarras, K Rosenzweig, D Korenstein, S Chimonas Jama 324 (17), 1785-1788, 2020 | 58 | 2020 |
| Show us the money: lessons in transparency from state pharmaceutical marketing disclosure laws S Chimonas, NM Rozario, DJ Rothman Health services research 45 (1), 98-114, 2010 | 56 | 2010 |
| Bringing transparency to medicine: exploring physicians' views and experiences of the sunshine act S Chimonas, NJ DeVito, DJ Rothman The American Journal of Bioethics 17 (6), 4-18, 2017 | 53 | 2017 |
| Managing conflicts of interest in clinical care: a national survey of policies at US medical schools S Chimonas, L Patterson, VH Raveis, DJ Rothman Academic Medicine 86 (3), 293-299, 2011 | 44 | 2011 |
| Despite The FDA’s Five-Year Plan, Black Patients Remain Inadequately Represented In Clinical Trials For Drugs: Study examines FDA’s five-year action plan aimed at improving … AK Green, N Trivedi, JJ Hsu, NL Yu, PB Bach, S Chimonas Health Affairs 41 (3), 368-374, 2022 | 35 | 2022 |
| Trends in industry payments to medical oncologists in the United States since the inception of the open payments program, 2014 to 2019 ES Tarras, DC Marshall, K Rosenzweig, D Korenstein, S Chimonas JAMA oncology 7 (3), 440-444, 2021 | 32 | 2021 |
| Mapping conflict of interests: scoping review S Chimonas, M Mamoor, SA Zimbalist, B Barrow, PB Bach, D Korenstein bmj 375, 2021 | 30 | 2021 |
| Academic medical centers' conflict of interest policies DJ Rothman, S Chimonas JAMA 304 (20), 2294-2295, 2010 | 28 | 2010 |
| Managing conflicts of interest in clinical care: the “race to the middle” at US medical schools S Chimonas, SD Evarts, SK Littlehale, DJ Rothman Academic Medicine 88 (10), 1464-1470, 2013 | 25 | 2013 |
| Association of medical students' reports of interactions with the pharmaceutical and medical device industries and medical school policies and characteristics: a cross … JS Yeh, KE Austad, JM Franklin, S Chimonas, EG Campbell, J Avorn, ... PLoS Medicine 11 (10), e1001743, 2014 | 18 | 2014 |
David RothmanPrrpifes在 columbia.edu 的电子邮件经过验证
